Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multiclass vs Standard ART in Acute HIV-1 Infection
NCT00525733Phase 2Completed
- Sponsor
- The Rockefeller University
- Start
- Oct 2007
- Primary completion
- Dec 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of raltegravir and maraviroc in human immunodeficiency virus type 1 infection (HIV-1) (2 arms), sponsored by The Rockefeller University. Primary endpoints: Proportion of Patients Having Detectable HIV-1 RNA Using the Single Copy Assay at 48 weeks and Cell associated HIV-1 RNA levels at 48 weeks. Started Oct 2007; status: completed.
02
Drugs
raltegravirmaraviroc
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT00525733.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00525733.